A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT03915379 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Acute
Myelodysplastic Syndromes

Interventions

DRUG: JNJ-67571244

Sponsor

Janssen Research & Development, LLC